Dihydropyrimidine Dehydrogenase Gene Variation and Severe 5-Fluorouracil Toxicity: A Haplotype Assessment
Pharmacogenomics2009Vol. 10(6), pp. 931–944
Citations Over TimeTop 10% of 2009 papers
Abstract
The association of a haplotype containing no nonsynonymous or splice-site polymorphisms indicates that additional important genetic variation may be located in noncoding gene regions. Furthermore, a comparison with other studies suggests that the relative importance of particular DPYD mutations (IVS14+1G>A and c.2846A>T) for predicting severe 5-FU toxicity differs geographically across Europe.
Related Papers
- → Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines(2021)48 cited
- → Ethnic Diversity of DPD Activity and the DPYD Gene: Review of the Literature(2021)43 cited
- → Implications of Dihydropyrimidine Dehydrogenase on 5-Fluorouracil Pharmacogenetics and Pharmacogenomics(2002)122 cited
- → The Role of Pharmacogenetics and Pharmacogenomics in Cancer Chemotherapy with 5-Fluorouracil(2000)83 cited
- → From Genes to Endogenous Substrates: Towards a Better Understanding of Drug Metabolizing Enzymes(2022)1 cited